News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: Nintedanib Extended Survival Beyond One Year for Advanced Adenocarcinoma Patients After Prior First-Line Chemotherapy


9/30/2013 11:04:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

INGELHEIM, Germany--(BUSINESS WIRE)-- New analysis of data from the LUME-Lung 1 Phase III clinical trial showed that the novel investigational compound nintedanib*, an oral triple angiokinase inhibitor that targets three receptors crucially involved in angiogenesis and tumour growth, provided a significant and clinically relevant overall survival benefit for advanced non-small cell lung cancer (NSCLC) patients with adenocarcinoma histology.1 The results were presented at the European Cancer Congress in Amsterdam.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES